The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Recent health news includes significant developments such as Akero Therapeutics' promising liver disease drug, potential ...

Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...

The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...

The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.